CODI Finance, Revolutionary IDO Launchpad On Solana Announces Launch of Staking Feature
KAUNAS, Lithuania, March 31, 2022 (GLOBE NEWSWIRE) -- The staking option for $CODI, CODI Finance's native token, is now available to the general public and, in particular, the CODI community.
CODI Finance's staking feature is now available on the CODI platform, intending to reward $CODI holders with staking rewards for securing the ecosystem. CODI Finance has made significant progress toward its vision of becoming a leading DEX and IDO launchpad in the Solana ecosystem and DeFi at large since its inception in September 2021.
CODI has decided to take it a step further by introducing high APY staking options on the CODI platform. As the governance token, $CODI would play an essential role in the future of the CODI Finance ecosystem and provide early access to retail investors for projects launching through the CODI IDO launchpad.
Bronze, Silver, Gold, Diamond, and Challenger are the five tiers of the staking feature. The Bronze tier is the lowest staking tier, requiring a minimum of 2000 $CODI tokens to be eligible, while the Silver tier is the next, requiring a minimum of 30,000 $CODI tokens. Gold, Diamond, and the highest staking tier, Challenger, require 225,000, 300,000, and 500,000 $CODI tokens. The APY on each tier varies, as do the staking rewards, depending on which tier is selected. Furthermore, once the IDO CODI launchpad is fully operational, members of the CODI community will be able to stake '$CODI' to invest in projects and receive early allocations.
$CODI can be purchased on Raydium, a leading Solana decentralized exchange, and p2pb2b, a well-known centralized cryptocurrency exchange. CODI was also recently added to one of the world's largest cryptocurrency ranking websites, Coingecko. Coingecko now allows the CODI finance community to track the daily price movement of $CODI and gain access to other CODI Finance data.
CODI also intends to list with a centralized exchange ranked in the top 25 on CoinmarketCap and other decentralized exchanges in the Solana ecosystem in the future.
CODI seeks to transform the current Solana IDO launchpad landscape based in Solana. The CODI community will run and own the ecosystem with a DAO governance model.
Please visit Codi.finance for more information.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3f92cc60-fb84-4e07-9399-ec322ef93bdbTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sampo plc’s share buybacks 13/05/202216.5.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 16/05/2022 at 08:30 am Sampo plc’s share buybacks 13/05/2022 On 13/05/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)25,54545.62AQEU38,57245.68CEUX9,72545.63TQEX96,15845.65XHELTOTAL170,00045.65 *rounded to two decimals On 30 March 2022, Sampo announced a share buyback programme of up to a maximum of EUR 250 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 31 March 2022, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 4,679,141 Sampo A shares representing 0.87 per cent of the total number of shares in Sampo plc. Details
Notes of the Board of Directors on Q1 202216.5.2022 07:30:00 CEST | Press release
NOTES OF THE BOARD OF DIRECTORS ON Q1 2022 REGULATED INFORMATION Brussels, 16 May 2022 07.30 am CEST KEY FIGURES For Q1 2022 we note the following key data: Net result of €21.8 million, or €2.18 per shareRental income up by €2.1 millionLoan-to-value on the investment portfolio down by two percentage points at 53.7%Sale of the buildings The Crescent (Anderlecht, Belgium) and Monnet 4 (Kirchberg, Luxembourg) resulting a profit of €5 millionThe average financing cost fell from 2.07% in 2021 to 2.05% on 31 March 2022Developments on Cloche d’Or continue apace, with the sale of the Kockelscheuer building in January 2022 and delivery of the Darwin II buildingAt the Tour&Taxis site the apartments of the first-phase of Park Lane are gradually being delivered, while events can once again take place in the Sheds, Maison de la Poste and Gare Maritime 16-05-2022-EN FINAL Attachment 16-05-2022-EN FINAL
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference16.5.2022 07:00:00 CEST | Press release
GENEVA, Switzerland May16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 10:30 a.m. EST on Tuesday, May 24, 2022. A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website. About ObsEva ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroi
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease16.5.2022 00:00:00 CEST | Press release
WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. “The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the tre
Cool Company Ltd. – Mandatory Notification of Trade15.5.2022 14:52:24 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Primary insider notification form